首页> 外文OA文献 >96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE

【2h】

96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE

机译：96O佐剂曲妥珠单抗（T-DM1）Emtansine（T-DM1）与HER2 +乳腺癌新辅助治疗后患者（PTS）中的患者（PTS）中的患者（PTS）：来自凯瑟琳的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
S. Loibl; C-S. Huang; M.S. Mano; T.P. Mamounas; C.E. Geyer; M. Untch; G. von Minckwitz; J-C. Thery; I. Schwaner; S. Limentani; N. Loman; K. Lübbe; J.C. Chang; T. Hatschek; D. Tesarowski; T. Boulet; C. Wiese; C. Song; N. Wolmark;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：佐剂曲妥珠单抗Emtansine（T-DM1）vs rastuzumab（h）患者残留侵入性疾病后Neoadjuvant治疗治疗Her2阳性乳腺癌：Katherine亚组分析
2. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study [J] . Huang Chiun-Sheng, Yang Youngsen, Kwong Ava, Breast cancer research and treatment. . 2021,第3期

机译：Trastuzumab Emtansine（T-DM1）与新辅助化疗后中国残留侵袭性疾病患者的曲妥珠单抗和HER2针对HER2阳性乳腺癌在3期凯瑟琳研究中
3. Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer [J] . Conte PierFranco, Schneeweiss Andreas, Loibl Sibylle, Cancer: A Journal of the American Cancer Society . 2020,第13期

机译：患者报告的凯瑟琳的结果：在人表皮生长因子受体2阳性乳腺癌中新辅助治疗后残留侵入性疾病患者辅助曲据患者的第3阶段研究
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Development of PET Imaging Probes for Predicting Response of Breast Cancer to Trastuzumab Emtansine (T-DM1) [D] . Al-saden, Noor. 2019

机译：宠物成像探针的发展，以预测乳腺癌对曲妥珠单抗的响应（T-DM1）
6. Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer [O] . PierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, -1

机译：凯瑟琳患者报告的结局：曲妥珠单抗氨丹宁与曲妥珠单抗辅助治疗在人类表皮生长因子受体2阳性乳腺癌新辅助治疗后残留浸润性疾病患者中进行的3期研究
7. Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain [O] . R Colomer, E Ciruelos, J De la Haba, 2016

机译：西班牙治疗腹膜康氏症患者腹膜癌患者腹膜癌，胸瘤和多西紫杉醇患者腹膜癌患者的新辅助化疗的成本实用性分析

96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE

著录项

相似文献

相关主题

期刊订阅